At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 222 enrolled
Drug / intervention
Dolutegravir / Lamivudine Pill +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine in Virologically-suppressed Adults Living With HIV on Bictegravir/Tenofovir Alafenamide/emtricitabine-the DYAD Study
In Brief
A Phase 4 clinical trial evaluating Dolutegravir / Lamivudine Pill and Bictegravir / Emtricitabine / Tenofovir Alafenamide Pill for HIV I Infection. Completed, enrolled 222 participants across 1 site.
Detailed Summary
Phase 4, randomized, open-label study to evaluate the efficacy, safety and tolerability of switching virologically suppressed adults living with HIV on bictegravir/tenofovir alafenamide/emtricitabine to dolutegravir/lamivudine
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV I Infection
CountriesUnited States
CollaboratorsViiV Healthcare
Timeline
Phase 4CompletedFinished
202120222023202420252026
Enrollment StartOct 2020
First PostedOct 2020
Primary CompletionAug 2023
Study CompletionAug 2023
TodayJul 2026
First PostedOct 14, 2020
Enrollment StartOct 5, 2020
Primary CompletionAug 3, 2023
Study CompletionAug 10, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.7 years ago
Interventions
Dolutegravir / Lamivudine Pilldrug
Experimental
Bictegravir / Emtricitabine / Tenofovir Alafenamide Pilldrug
Active comparator